Navigation Links
Clinical technique sets new standard for speed in battle to prevent pandemic infection
Date:1/25/2012

A new diagnosis technique developed by researchers at the RIKEN Omics Science Center (OSC) has succeeded in detecting influenza virus infection in only 40 minutes and with one hundred times the sensitivity of conventional methods. Clinical research conducted in 2009 and 2010 confirms the new technique accurately identified the 2009 pandemic (pdm) influenza virus in Japanese patients less than 24 hours after fever onset, much faster than standard diagnostic tests.

The human-to-human transmission of new, highly pathogenic strains of influenza virus poses today a major threat to human health and to the security of global society. With its rapid global spread, the 2009 pandemic (pdm) influenza virus reminded the world of this threat, resulting in an estimated 18,000 deaths worldwide. In Japan, infected patients over the winter season of 2009 accounted for a staggering 16% of the total population.

Tackling the challenge of such global pandemics requires new technology for rapid clinical diagnosis. To answer this need, Toshihisa Ishikawa and colleagues at the RIKEN OSC developed the RT-SmartAmp assay, a technique to rapidly detect the 2009 pdm influenza A(H1N1) virus from patient swab samples. By combining both reverse transcriptase (RT) and isothermal DNA amplification reactions in one step, the RT-SmartAmp assay does away with the need for RNA extraction and PCR reaction. The researchers adapted the RT-SmartAmp technique using a fluorescent primer to specifically detect the 2009 pdm influenza A(H1N1) virus within 40 minutes, without cross-reacting with the seasonal A(H1N1), A(H3N2), or B-type (Victoria) viruses.

The effectiveness of the RT-SmartAmp method was confirmed in clinical research carried out at Japanese hospitals during the period of October 2009 to January 2010, where it outperformed standard diagnosis tests in both speed and sensitivity. Of a total 255 clinical samples, 140 (54.9%) were identified as 2009 pdm A(H1N1)-positive by RT-SmartAmp, compared to only 110 (43.1%) detected by standard diagnostic tests. In 72.8% of all 140 infection-positive cases, the RT-SmartAmp assay detected the presence of the pdm influenza virus within 24 hours of fever onset.

Taken together, these results set a new standard for infection diagnosis speed, providing a highly-effective tool for rapidly detecting sub-types of the H5N1 virus and oseltamivir-resistant influenza viruses and promising support in the battle to prevent global pandemic infection.


'/>"/>

Contact: RIKEN Global Relations Office
gro-pr@riken.jp
RIKEN
Source:Eurekalert

Related biology technology :

1. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
2. MarketsandMarkets: Global Clinical Trial Management Systems Market Worth $1300.4 Million by 2016
3. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
4. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
5. Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis
6. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
7. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
8. NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011
9. Celtaxsys Acquires Clinical Stage Innate Immunity Drug for Inflammation
10. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
11. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):